Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB

Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1199-203. doi: 10.1161/01.ATV.0000131266.38312.2e. Epub 2004 May 6.

Abstract

Objective: Several proinflammatory cytokines including IL-6 and IL-8 are produced by human adipocytes, but it is still unclear how this process is regulated. Angiotensin (Ang) II, which is also produced by adipocytes, might play a role as a regulator. In the present study, we investigated the effect of Ang II on the production of IL-6 and IL-8 in in vitro differentiated human adipocytes.

Methods and results: Isolation of preadipocytes and differentiation of these cells into adipocytes, Real-time quantitative reverse-transcriptase polymerase chain reaction, Western-blot, enzyme-linked immunosorbent assay, and electromobility shift assay. Ang II-stimulated IL-6 and IL-8 mRNA expression and protein release in a time- and concentration-dependent way. This action of Ang II was completely blocked by the NF-kappaB-blocker Bay 117082 and the AT1 blocker candesartan, but only partially by the AT2-blocker PD 123 319. Incubation of adipocytes with Ang II resulted in an increased phosphorylation of the p65 subunit of NF-kappaB and an increased translocation of NF-kappaB to the nucleus.

Conclusions: Ang II stimulates IL-6 and IL-8 production and release from human adipocytes by a NF-kappaB-dependent pathway. This proinflammatory action of Ang II seems to be mediated by the AT1 and less by the AT2 receptor subtype.

MeSH terms

  • Adipocytes / drug effects*
  • Adipocytes / metabolism
  • Adult
  • Angiotensin II / antagonists & inhibitors
  • Angiotensin II / pharmacology*
  • Angiotensin II Type 1 Receptor Blockers / pharmacology*
  • Angiotensin II Type 2 Receptor Blockers
  • Benzimidazoles / pharmacology
  • Biphenyl Compounds
  • Cells, Cultured / drug effects
  • Cells, Cultured / metabolism
  • Electrophoretic Mobility Shift Assay
  • Female
  • Humans
  • Imidazoles / pharmacology
  • Inflammation
  • Interleukin-6 / biosynthesis
  • Interleukin-6 / genetics
  • Interleukin-6 / metabolism*
  • Interleukin-8 / biosynthesis
  • Interleukin-8 / genetics
  • Interleukin-8 / metabolism*
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / metabolism*
  • Nitriles / pharmacology
  • Phosphorylation / drug effects
  • Protein Processing, Post-Translational / drug effects
  • Protein Transport / drug effects
  • Pyridines / pharmacology
  • RNA, Messenger / biosynthesis
  • Receptor, Angiotensin, Type 1 / drug effects*
  • Receptor, Angiotensin, Type 1 / physiology
  • Sulfones / pharmacology
  • Tetrazoles / pharmacology
  • Transcription Factor RelA
  • Transcriptional Activation / drug effects

Substances

  • 3-(4-methylphenylsulfonyl)-2-propenenitrile
  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin II Type 2 Receptor Blockers
  • Benzimidazoles
  • Biphenyl Compounds
  • Imidazoles
  • Interleukin-6
  • Interleukin-8
  • NF-kappa B
  • Nitriles
  • Pyridines
  • RNA, Messenger
  • Receptor, Angiotensin, Type 1
  • Sulfones
  • Tetrazoles
  • Transcription Factor RelA
  • Angiotensin II
  • PD 123319
  • candesartan